This Pill Could Reduce The Chance Of A Heart Attack

The anticholesterol drug Mevacor was already generating nearly $1 billion in sales annually for Merck & Co. Then came word of a study that suggests strongly that the drug can curb a leading cause of heart attacks. The drug packs such a punch against the fatty arterial deposits known as plaque that the scientists conducting the study announced on Nov. 20 that they had canceled plans to extend their research for another year and a half.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.